| melanoma
Braftovi vs Tecentriq
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Braftovi vs Tecentriq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecentriq has a higher rate of injection site reactions vs Braftovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecentriq but not Braftovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Braftovi
Tecentriq
At A Glance
Oral
Once daily
BRAF inhibitor
IV infusion
Every 2-4 weeks
PD-L1 antagonist
Indications
- melanoma
- Colorectal Carcinoma
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Liver carcinoma
- Melanoma
- Alveolar Soft Part Sarcoma
Dosing
melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.
Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.
Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.
Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.
Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.
Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.
Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.
Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.
Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).
Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.
Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.
Pharmacology
Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.
Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Braftovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tecentriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Braftovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Tecentriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Braftovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tecentriq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Braftovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tecentriq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BraftoviView full Braftovi profile
TecentriqView full Tecentriq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.